1. Field of the Invention
This invention is generally related to bioabsorbable devices having RGD attached thereto.
2. Description of the State of the Art
Percutaneous coronary intervention (PCI) is a procedure for treating heart disease. A catheter assembly having a balloon portion is introduced percutaneously into the cardiovascular system of a patient via the brachial or femoral artery. The catheter assembly is advanced through the coronary vasculature until the balloon portion is positioned across the occlusive lesion. Once in position across the lesion, the balloon is inflated to a predetermined size to radially compress the atherosclerotic plaque of the lesion to remodel the lumen wall. The balloon is then deflated to a smaller profile to allow the catheter to be withdrawn from the patient's vasculature.
Problems associated with the above procedure include formation of intimal flaps or torn arterial linings which can collapse and occlude the blood conduit after the balloon is deflated. Moreover, thrombosis and restenosis of the artery may develop over several months after the procedure, which may require another angioplasty procedure or a surgical by-pass operation. To reduce the partial or total occlusion of the artery by the collapse of the arterial lining and to reduce the chance of thrombosis or restenosis, a stent is implanted in the artery to keep the artery open.
Drug delivery stents have reduced the incidence of in-stent restenosis (ISR) after PCI (see, e.g., Serruys, P. W., et al., J. Am. Coll. Cardiol. 39:393-399 (2002)), which has plagued interventional cardiology for more than a decade. However, ISR still poses a significant problem given the large volume of coronary interventions and their expanding use. The pathophysiological mechanism of ISR involves interactions between the cellular and acellular elements of the vessel wall and the blood. Damage to the endothelium during PCI constitutes a major factor for the development of ISR (see, e.g., Kipshidze, N., et al., J. Am. Coll. Cardiol. 44:733-739 (2004)).
The polypeptide Arg-Gly-Asp (RGD) has been demonstrated to be a bioactive factor for human endothelial cell attachment. It also has been shown that on a polymer surface having RGD chemically bonded to the surface, the growth rate of human endothelial cells can be increased (see, Ruoslahti, E., et al. Science 238:491-497 (1987)). However, this study fails to take into account the accessibility of the RGD to the endothelial progenitor cells (EPCs) so that the endothelial cell growth enhancing effect described therein is limited.
Therefore, there is a need for an attractant attached to a surface for endothelial progenitor cells.
There is a further need for an attractant attached to a surface that provides for improved accessibility of the attractant.
The embodiments of the present invention address these concerns as well as others that are apparent to one having ordinary skill in the art.
Provided herein is a bioabsorbable stent including a chemo-attractant for endothelial progenitor cells (EPCs). The chemo-attractant is chemically bonded to the bioabsorbable stent via a spacer compound. In some embodiments, the spacer compound comprises a hydrophobic moiety and a hydrophilic moiety. The spacer compound can be grafted to the surface of the bioabsorbable stent. The hydrophobic moiety can be embedded in the stent, and the chemo-attractant can be attached to the hydrophilic moiety. Upon implantation, the hydrophilic moiety can be projected from the surface of the medical device toward a physiologic environment. The chemo-attractant can then recruit EPCs so as to enhance the growth rate of endothelium on the surface of the device. It is important to note that a linker of this construct allows for more freedom for EPCs to access to the chemo-attractant so that the regeneration rate of endothelium on the surface can be enhanced.
In some embodiments, the medical device described herein can further include a bioactive agent. Some examples of the bioactive agent include, but are not limited to, paclitaxel, docetaxel, estradiol, nitric oxide donors, super oxide dismutases, super oxide dismutases mimics, 4-amino-2,2,6,6-tetramethylpiperidine-1-oxyl (4-amino-TEMPO), tacrolimus, dexamethasone, rapamycin, rapamycin derivatives, 40-O-(2-hydroxy)ethyl-rapamycin (everolimus), 40-O-(3-hydroxy)propyl-rapamycin, 40-O-[2-(2-hydroxy)ethoxy]ethyl-rapamycin, and 40 O-tetrazole-rapamycin, 40-epi-(N1-tetrazolyl)-rapamycin (ABT-578), pimecrolimus, imatinib mesylate, midostaurin, clobetasol, mometasone, CD-34 antibody, abciximab (REOPRO), progenitor cell capturing antibody, prohealing drugs, prodrugs thereof, co-drugs thereof, or a combination thereof.
The medical device described herein can be formed on a medical device for treating, preventing, or ameliorating a medical condition such as atherosclerosis, thrombosis, restenosis, hemorrhage, vascular dissection or perforation, vascular aneurysm, vulnerable plaque, chronic total occlusion, claudication, anastomotic proliferation (for vein and artificial grafts), bile duct obstruction, ureter obstruction, tumor obstruction, or combinations of these.
Provided herein is a bioabsorbable stent including a chemo-attractant for endothelial progenitor cells (EPCs). The chemo-attractant is chemically bonded to the bioabsorbable stent via a spacer compound. In some embodiments, the spacer compound comprises a hydrophobic moiety and a hydrophilic moiety. The spacer compound can be grafted to the surface of the bioabsorbable stent. The hydrophobic moiety can be embedded in the stent, and the chemo-attractant can be attached to the hydrophilic moiety. Upon implantation, the hydrophilic moiety can be projected from the surface of the medical device toward a physiologic environment. The chemo-attractant can then recruit EPCs so as to enhance the growth rate of endothelium on the surface of the device. It is important to note that a spacer compound of the present invention allows for more freedom for EPCs to access to the chemo-attractant so that the regeneration rate of endothelium on the surface can be enhanced.
In some embodiments, the medical device described herein can include a bioactive agent. Some examples of the bioactive agent include siRNA and/or other oligonucleotides that inhibit endothelial cell migration. The bioactive agent can also be lysophosphatidic acid (LPA) or sphingosine-1-phosphate (SIP). LPA is a “bioactive” phospholipid able to generate growth factor-like activities in a wide variety of normal and malignant cell types. LPA plays an important role in normal physiological processes such as wound healing, and in vascular tone, vascular integrity, or reproduction. Some other exemplary bioactive agents are paclitaxel, docetaxel, estradiol, 17-beta-estradiol, nitric oxide donors, super oxide dismutases, super oxide dismutases mimics, 4-amino-2,2,6,6-tetramethylpiperidine-1-oxyl (4-amino-TEMPO), biolimus, tacrolimus, dexamethasone, rapamycin, rapamycin derivatives, 40-O-(2-hydroxy)ethyl-rapamycin (everolimus), 40-O-(3-hydroxy)propyl-rapamycin, 40-O-[2-(2-hydroxy)ethoxy]ethyl-rapamycin, and 40-O-tetrazole-rapamycin, 40-epi-(N1-tetrazolyl)-rapamycin (ABT-578), ÿ-hiridun, clobetasol, pimecrolimus, imatinib mesylate, midostaurin, prodrugs thereof, co-drugs thereof, and combinations thereof.
The medical device such as a stent, can be implanted in a patient to treat, prevent, mitigate, or reduce a vascular medical condition, or to provide a pro-healing effect. Examples of these conditions include atherosclerosis, thrombosis, restenosis, hemorrhage, vascular dissection or perforation, vascular aneurysm, vulnerable plaque, chronic total occlusion, claudication, anastomotic proliferation (for vein and artificial grafts), bile duct obstruction, ureter obstruction, tumor obstruction, or combinations of these.
As used herein, the chemo-attractant includes any synthetic or natural molecules capable of attracting endothelial cells. In some embodiments, the chemo-attractant includes any synthetic or natural molecules capable of attracting an effective number of endothelial cells. The attractant generally has a degree of selectivity towards these cells. The chemo-attractant also includes any synthetic or natural molecules capable of binding to adhesion receptors differentially expressed on the endothelial cells. One such adhesion receptor can be integrin. Some exemplary chemo-attractants include, but are not limited to, small integrin-binding molecules, RGD peptide or cyclic RGD peptide (cRGD), synthetic cyclic RGD (cRGD) mimetics, and small molecules binding to other adhesion receptors differentially expressed on the endothelial cells.
In some embodiments, the chemo-attractant can be those molecules capable of binding to ICAM (intercellular adhesion molecule) molecules or VCAM (vascular cell adhesion molecule) molecules, which are present in the endothelial cells. Such chemo-attractant can be, for example, receptors binding to ICAM or VCAM in the endothelial cells, which can include, but are not limited to, Decoy receptor 3 (DcR3), a tumor necrosis factor (TNF) that preferentially binds to ICAM and VCAM—2, integrin LFA-1 (LFA-1Af) (expressed on lymphocytes), which has conformational changes in extracellular domains enabling higher affinity binding to the ligand ICAM-1, or combinations thereof.
In some embodiments, the chemo-attractant can specifically exclude a particular chemo-attractant described above.
The cRGD or RGD mimetics described herein includes any peptides or peptide mimetics that result from the modification of the cyclic Arg-Gly-Asp peptide. The modification can be on the pendant groups and/or on the backbone of the peptide. Peptide synthesis, including the synthesis of peptide mimetics, is well documented and can be readily achieved using, for example, combinatorial chemistry.
Some examples of cRGD or RGD mimetics include v3 antagonists such as IIb/IIIb antagonists (Coller, B. S., Thromb. Haemost. 86(1):427-43 (2001) (Review)), one example of which is Abciximax (Blindt, R., J. Mol. Cell. Cardiol. 32:2195-2206 (2000)), XJ 735 (Srivatsa, S. S., et al., Cardiovasc. Res. 36:408-428 (1997)), anti-3-integrin antibody F11, cRGD (Sajid, M., et al., Am. J. Physiol. Cell Physiol., 285:C1330-1338 (2003), and other sequences such as laminin derived SIKVAV (Fittkau, M. H., et al., Biomaterials, 26:167-174 (2005)), laminin derived YIGSR (Kouvroukoglou, S., et al., Biomaterials, 21:1725-1733 (2000)), KQAGDV, and VAPG (Mann, B. K., J. Biomed. Mater. Res. 60(1):86-93 (2002)). The following describes a basic procedure for the synthesis of a peptide, including a peptide mimetics:
Before the peptide synthesis starts, the amine end of the amino acid (starting material) is protected with FMOC (9-fluoromethyl carbamate) or other protective groups, and a solid support such as a Merrifield resin (free amines) is used as an initiator. Then, step (1) through step (3) reactions are performed and repeated until the desired peptide is obtained: (1) a free amine is reacted with the carboxyl end using carbodiimide chemistry, (2) the amino acid sequence is purified, and (3) the protecting group, e.g., the FMOC protecting group, is removed under mildly acidic conditions to yield a free amine. The peptide can then be cleaved from the resin to yield a free standing peptide or peptide mimetic.
In some embodiments, a coating can specifically exclude any of the above mentioned chemo-attractant. For example, a coating can specifically exclude RGD peptide or cyclic RGD peptide (cRGD).
In some embodiments, the spacer compound can have a phospholipid moiety as the hydrophobic moiety. Any phospholipid can be incorporated into the spacer compound. For example, the phospholipid can be phosphatidylcholine, phosphatidylethanolamine, phosphatidic Acid, phosphatidylserine, phosphatidylglycerol, cardiolipin, or phosphatidylinositol.
In some embodiments, the spacer compound can have a hydrophilic moiety which is PEG. In these embodiments, the hydrophobic moiety of the spacer compound can be grafted to or embedded within the surface of the medical device. Upon placed in a physiological environment, the PEG moiety can project from the surface to allow attachment of a chemo-attractant to the PEG moiety. For example, the spacer compound can have a structure of
which is DMPE-PEG 3000. Conformational studies on DMPE-PEG 3000 showed that this molecule has a bulk PEG head group and a relatively small phospholipids tail (
The PEG moiety can have different molecular weights. Generally, the molecular weight of PEG shall be below about 20,000 Daltons so as to allow the PEG to be excreted from the body. Some exemplary ranges of the molecular weight of PEG can be from about 300 Daltons to about 15,000 Daltons, about 1000 Daltons to about 10,000. Daltons, about 2000 Daltons to about 5000 Daltons or about 4000 Daltons.
In some embodiments, the spacer compound can be a di-block copolymer that includes a polymeric hydrophobic block and a polymeric hydrophilic block having a general formula of [hydrophobic polymer]-block-[hydrophilic polymer]. The hydrophobic block can be any hydrophobic polymer. In some embodiments, the hydrophobic polymer can be selected from poly(ester amide), polyhydroxyalkanoates (PHA), poly(3-hydroxyalkanoates) such as poly(3-hydroxypropanoate), poly(3-hydroxybutyrate), poly(3-hydroxyvalerate), poly(3-hydroxyhexanoate), poly(3-hydroxyheptanoate) and poly(3-hydroxyoctanoate), poly(4-hydroxyalkanaote) such as poly(4-hydroxybutyrate), poly(4-hydroxyvalerate); poly(4-hydroxyhexanote), poly(4-hydroxyheptanoate), poly(4-hydroxyoctanoate) and copolymers including any of the 3-hydroxyalkanoate or 4-hydroxyalkanoate monomers described herein or blends thereof, poly(D,L-lactide), poly(L-lactide), polyglycolide, poly(D,L-lactide-co-glycolide), poly(L-lactide-co-glycolide), polycaprolactone, poly(lactide-co-caprolactone), poly(glycolide-co-caprolactone), poly(dioxanone), poly(ortho esters), poly(anhydrides), poly(tyrosine carbonates) and derivatives thereof, poly(tyrosine ester) and derivatives thereof, poly(imino carbonates), poly(glycolic acid-co-trimethylene carbonate), polyphosphoester, polyphosphoester urethane, poly(amino acids), polycyanoacrylates, poly(trimethylene carbonate), poly(iminocarbonate), polyurethanes, polyphosphazenes, silicones, polyesters, polyolefins, polyisobutylene and ethylene-alphaolefin copolymers, acrylic polymers and copolymers, vinyl halide polymers and copolymers, such as polyvinyl chloride, polyvinyl ethers, such as polyvinyl methyl ether, polyvinylidene halides, such as polyvinylidene chloride, polyacrylonitrile, polyvinyl ketones, polyvinyl aromatics, such as polystyrene, polyvinyl esters, such as polyvinyl acetate, copolymers of vinyl monomers with each other and olefins, such as ethylene-methyl methacrylate copolymers, acrylonitrile-styrene copolymers, ABS resins, and ethylene-vinyl acetate copolymers, polyamides, such as Nylon 66 and polycaprolactam, alkyd resins, polycarbonates, polyoxymethylenes, polyimides, polyethers, poly(glyceryl sebacate), poly(propylene fumarate), poly(n-butyl methacrylate), poly(sec-butyl methacrylate), poly(isobutyl methacrylate), poly(tert-butyl methacrylate), poly(n-propyl methacrylate), poly(isopropyl methacrylate), poly(ethyl methacrylate), poly(methyl methacrylate), polyurethanes, polyalkylene oxalates, polyphosphazenes, or poly(aspirin). In some embodiments, the copolymer described herein can exclude any one of the aforementioned polymers.
The hydrophobic moiety and the hydrophilic moiety shall have a molecular weight or degrade into fragments having a molecular weight ranging from about 20,000 Daltons so as to allow the PEG to be excreted from the body. For example, such a di-blockcopolymer can be poly(L-lactide-co-PEG (3000)).
In some embodiments, the spacer compound can include other hydrophilic moieties. For example, such other hydrophilic moieties can be, poly(alkylene oxide), poly(vinyl alcohol) or poly(ethylene glycol).
The chemo-attractant can be attached to the spacer compound described herein via a linkage. The linkage can be degradable or non-degradable. Degradable linkages can be hydrolytically degradable linkages or enzymatically degradable linkages. A hydrolytically degradable linkage can link the chemo-attractant and the spacer compound via the linkage's reactive groups. For example, in some embodiments, the linkage can be an amino acid group that includes amino, thiol, and/or carboxylic groups. Some exemplary strategies for forming hydrolytically degradable linkages include:
(1) ε-Amino group of lysine (which can be integrated into a polymer) and α-amino group of a protein. The amine can be on the polymer backbone (with or without a spacer compound, e.g., PEG, or an alkyl chain). This can yield an amide, thiourea, alkylamine or urethane linkage.
(2) Thiol group or a free cysteine, which forms a thioether linkage.
(3) Thiol group on a cysteine, which can be conjugated with vinylsulfone (R—SO2—CH═CH2).
(4) Carboxylic acid groups on the aspartic and glutamic acid.
Some examples of hydrolytically degradable linkages include amide linkages that can be generated by reacting an amine group with succinate esters such as N-hydroxysuccinimide (NHS), thiol linkages such as disulfide (R-L1-S—S-L2-R′) where the length of the linker L1 and L2 control the hydrolization, or ester bonds formed by coupling the peptide's carboxylic end with a hydroxyl on the polymer backbone (with or without a spacer compound, e.g., PEG, or an alkyl chain). Esterification can be carried out using established methods in the art (e.g., carbodiimide chemistry in the presence of 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide (EDC)).
Enzymatically degradable linkages can be degraded by an enzyme, often to target a specific area of the body or organ. In other words, the stimulus for an enzymatically degradable linkage is the presence of an enzyme. For example, a specific dipeptide sequence can be incorporated into the linkage, which can be cleaved by an enzyme. Some examples of enzymatically degradable linkages include, but are not limited to, self-immolative p-aminobenzyloxycarbonyl (PABC) spacer compound between the dipeptide and the polymer, dipeptides such as phenylaniline-lysine and valine-cysteine, or PEG/dipeptide linkages such as alanyl-valine, alanyl-proline and glycyl-proline.
In some embodiments, the chemo-attractant can be attached to the hydrophilic moiety in the spacer compound by using a photosensitive moiety. In some embodiments, the photosensitive moiety can be, e.g., (N-succinimidyl-6-[4′-azido-2′-nitrophenylamino]-hexanoate). An example of using this photosensitive moiety to attach RGD to PEG is described by Chung et al., J. Biomed. Mater. Res. Part A, vol. 72A(2):213-219 (2005).
Some other linkages can be found at “Biodegradable Polymers for Protein and Peptide Drug Delivery” Bioconjugate Chem. 1995, 6:332-351; M. P. Lutolf and J. A. Hubbell, Biomacromolecules 2003, 4:713-722; and U.S. patent application Ser. No. 10/871,658. Some additional representative linking chemistry is described in U.S. patent application Ser. No. 10/871,658, the entire disclosure of which is hereby incorporated by reference.
The chemo-attractant can be attached to the spacer compound described prior to or after the spacer compound is applied to the surface of the medical device. In some embodiments, the spacer compound can be applied to the surface of the medical device prior to the surface attachment of the chemo-attractant to the spacer compound. In some embodiments, the spacer compound can be applied to the surface of a medical device after the chemo-attractant is attached to the spacer compound.
The spacer compound can be applied to the surface of a bioabsorbable medical device by an established method of forming a coating. For example, spacer compound can be spray coated onto the surface of a medical device (e.g., a bioabsorbable stent). The spacer compound will then phase separate, with the hydrophobic moiety of the spacer compound being embedded within the surface layer of the medical device and the hydrophilic moiety projecting from the surface of the medical device.
The embedding of the hydrophobic moiety of the spacer compound can be achieved by using an appropriate solvent in coating the spacer compound. For example, the solvent can be chosen so that it can dissolve the spacer compound and dissolve, swell or plasticize a polymer on the surface of the medical device, which can be a coating surface or surface of the medical device itself. The solvent provides the opportunity for the hydrophobic moiety of the spacer compound to entangle with or embed within the top layer of the dissolved, swelled, or plasticized surface of the medical device. The solvent can be a single solvent or a mixture of solvents. In the mixture of solvents, the solvents shall be mutually miscible or substantially miscible. In some embodiments, the solvent can be a mixture of a solvent for the spacer compound and a solvent for a polymer on the surface of the medical device.
Grafting the spacer compound to the medical device can be achieved by the methods revealed in Nam, Y, et al. Biotechnology letters 2093-98 (2002).
In some embodiments, the spacer compound can be attached, embedded or grafted to the surface of a medical device after the chemo-attractant has been attached to the spacer compound via the linkage describe above. The spacer compound with the chemo-attractant can be the spray coated onto the surface of a medical device as described above.
The medical device having the features described herein can include any biocompatible polymer. The biocompatible polymer can be biodegradable (both bioerodable or bioabsorbable) or nondegradable and can be hydrophilic or hydrophobic.
Representative biocompatible polymers include, but are not limited to, poly(ester amide), polyhydroxyalkanoates (PHA), poly(3-hydroxyalkanoates) such as poly(3-hydroxypropanoate), poly(3-hydroxybutyrate), poly(3-hydroxyvalerate), poly(3-hydroxyhexanoate), poly(3-hydroxyheptanoate) and poly(3-hydroxyoctanoate), poly(4-hydroxyalkanaote) such as poly(4-hydroxybutyrate), poly(4-hydroxyvalerate), poly(4-hydroxyhexanote), poly(4-hydroxyheptanoate), poly(4-hydroxyoctanoate) and copolymers including any of the 3-hydroxyalkanoate or 4-hydroxyalkanoate monomers described herein or blends thereof, poly(D,L-lactide), poly(L-lactide), polyglycolide, poly(D,L-lactide-co-glycolide), poly(L-lactide-co-glycolide), polycaprolactone, poly(lactide-co-caprolactone), poly(glycolide-co-caprolactone), poly(dioxanone), poly(ortho esters), poly(anhydrides), poly(tyrosine carbonates) and derivatives thereof, poly(tyrosine ester) and derivatives thereof, poly(imino carbonates), poly(glycolic acid-co-trimethylene carbonate), polyphosphoester, polyphosphoester urethane, poly(amino acids), polycyanoacrylates, poly(trimethylene carbonate), poly(iminocarbonate), polyurethanes, polyphosphazenes, silicones, polyesters, polyolefins, polyisobutylene and ethylene-alphaolefin copolymers, acrylic polymers and copolymers, vinyl halide polymers and copolymers, such as polyvinyl chloride, polyvinyl ethers, such as polyvinyl methyl ether, polyvinylidene halides, such as polyvinylidene chloride, polyacrylonitrile, polyvinyl ketones, polyvinyl aromatics, such as polystyrene, polyvinyl esters, such as polyvinyl acetate, copolymers of vinyl monomers with each other and olefins, such as ethylene-methyl methacrylate copolymers, acrylonitrile-styrene copolymers, ABS resins, and ethylene-vinyl acetate copolymers, polyamides, such as Nylon 66 and polycaprolactam, alkyd resins, polycarbonates, polyoxymethylenes, polyimides, polyethers, poly(glyceryl sebacate), poly(propylene fumarate), poly(n-butyl methacrylate), poly(sec-butyl methacrylate), poly(isobutyl methacrylate), poly(tert-butyl methacrylate), poly(n-propyl methacrylate), poly(isopropyl methacrylate), poly(ethyl methacrylate), poly(methyl methacrylate), epoxy resins, polyurethanes, rayon, rayon-triacetate, cellulose acetate, cellulose butyrate, cellulose acetate butyrate, cellophane, cellulose nitrate, cellulose propionate, cellulose ethers, carboxymethyl cellulose, polyethers such as poly(ethylene glycol) (PEG), copoly(ether-esters) (e.g. poly(ethylene oxide/poly(lactic acid) (PEO/PLA)), polyalkylene oxides such as poly(ethylene oxide), poly(propylene oxide), poly(ether ester), polyalkylene oxalates, polyphosphazenes, phosphoryl choline, choline, poly(aspirin), polymers and co-polymers of hydroxyl bearing monomers such as 2-hydroxyethyl methacrylate (HEMA), hydroxypropyl methacrylate (HPMA), hydroxypropylmethacrylamide, PEG acrylate (PEGA), PEG methacrylate, 2-methacryloyloxyethylphosphorylcholine (MPC) and n-vinyl pyrrolidone (VP), carboxylic acid bearing monomers such as methacrylic acid (MA), acrylic acid (AA), alkoxymethacrylate, alkoxyacrylate, and 3-trimethylsilylpropyl methacrylate (TMSPMA), poly(styrene-isoprene-styrene)-PEG (SIS-PEG), polystyrene-PEG, polyisobutylene-PEG, polycaprolactone-PEG (PCL-PEG), PLA-PEG, poly(methyl methacrylate)-PEG (PMMA-PEG), polydimethylsiloxane-co-PEG (PDMS-PEG), poly(vinylidene fluoride)-PEG (PVDF-PEG), PLURONIC™ surfactants (polypropylene oxide-co-polyethylene glycol), poly(tetramethylene glycol), hydroxy functional poly(vinyl pyrrolidone), biomolecules such as chitosan, alginate, fibrin, fibrinogen, cellulose, starch, dextran, dextrin, fragments and derivatives of hyaluronic acid, heparin, fragments and derivatives of heparin, glycosamino glycan (GAG), GAG derivatives, polysaccharide, chitosan, alginate, or combinations thereof. In some embodiments, the copolymer described herein can exclude any one of the aforementioned polymers.
As used herein, the terms poly(D,L-lactide), poly(L-lactide), poly(D,L-lactide-co-glycolide), and poly(L-lactide-co-glycolide) can be used interchangeably with the terms poly(D,L-lactic acid), poly(L-lactic acid), poly(D,L-lactic acid-co-glycolic acid), or poly(L-lactic acid-co-glycolic acid), respectively.
In some embodiments, the surface layer of the medical device can include a biobeneficial material. The combination can be mixed, blended, or patterned or arranged in separate layers. The biobeneficial material useful in the coatings described herein can be polymeric or non-polymeric. The biobeneficial material is preferably non-toxic, non-antigenic and non-immunogenic enough so that it can be successfully introduced into a patient. A biobeneficial material is one which enhances the biocompatibility of a device by being non-fouling, hemocompatible, actively non-thrombogenic, or anti-inflammatory, all without depending on the release of a pharmaceutically active agent.
Representative biobeneficial materials include, but are not limited to, polyethers such as poly(ethylene glycol), copoly(ether-esters), polyalkylene oxides such as poly(ethylene oxide), poly(propylene oxide), poly(ether ester), polyalkylene oxalates, polyphosphazenes, phosphoryl choline, choline, poly(aspirin), polymers and co-polymers of hydroxyl bearing monomers such as hydroxyethyl methacrylate (HEMA), hydroxypropyl methacrylate (HPMA), hydroxypropylmethacrylamide, poly (ethylene glycol) acrylate (PEGA), PEG methacrylate, 2-methacryloyloxyethylphosphorylcholine (MPC) and n-vinyl pyrrolidone (VP), carboxylic-acid-bearing monomers such as methacrylic acid (MA), acrylic acid (AA), alkoxymethacrylate, alkoxyacrylate, and 3-trimethylsilylpropyl methacrylate (TMSPMA), poly(styrene-isoprene-styrene)-PEG (SIS-PEG), polystyrene-PEG, polyisobutylene-PEG, polycaprolactone-PEG (PCL-PEG), PLA-PEG, poly(methyl methacrylate)-PEG (PMMA-PEG), polydimethylsiloxane-co-PEG (PDMS-PEG), poly(vinylidene fluoride)-PEG (PVDF-PEG), PLURONIC™ surfactants (polypropylene oxide-co-polyethylene glycol), poly(tetramethylene glycol), hydroxy functional poly(vinyl pyrrolidone), biomolecules such as fibrin, fibrinogen, cellulose, starch, dextran, dextrin, hyaluronic acid, fragments and derivatives of hyaluronic acid, heparin, fragments and derivatives of heparin, glycosamino glycan (GAG), GAG derivatives, polysaccharide, chitosan, alginate, silicones, PolyActive™, and combinations thereof. In some embodiments, the coating can exclude any one of the aforementioned polymers.
The term PolyActive™ refers to a block copolymer having flexible poly(ethylene glycol) and poly(butylene terephthalate) blocks (PEGT/PBT). PolyActive™ is intended to include AB, ABA, BAB copolymers having such segments of PEG and PBT (e.g., poly(ethylene glycol)-block-poly(butyleneterephthalate)-block poly(ethylene glycol) (PEG-PBT-PEG).
In some embodiments, the medical device having the features described herein can optionally include one or more bioactive agents. These bioactive agents can be any agent which is a therapeutic, prophylactic, or diagnostic agent. These agents can have anti-proliferative or anti-inflammatory properties or can have other properties such as antineoplastic, antiplatelet, anti-coagulant, anti-fibrin, antithrombonic, antimitotic, antibiotic, antiallergic, or antioxidant properties. These agents can be cystostatic agents, agents that promote the healing of the endothelium (other than by releasing or generating NO), or agents that promote the attachment, migration and proliferation of endothelial cells while quenching smooth muscle cell proliferation. Examples of suitable therapeutic and prophylactic agents include synthetic inorganic and organic compounds, proteins and peptides, polysaccharides and other sugars, lipids, and DNA and RNA nucleic acid sequences having therapeutic, prophylactic or diagnostic activities. Nucleic acid sequences include genes, antisense molecules, which bind to complementary DNA to inhibit transcription, and ribozymes. Some other examples of bioactive agents include antibodies, receptor ligands, enzymes, adhesion peptides, blood clotting factors, inhibitors or clot dissolving agents, such as streptokinase and tissue plasminogen activator, antigens for immunization, hormones and growth factors, oligonucleotides such as antisense oligonucleotides and ribozymes and retroviral vectors for use in gene therapy. Examples of anti-proliferative agents include rapamycin and its functional or structural derivatives, 40-O-(2-hydroxy)ethyl-rapamycin (everolimus), and its functional or structural derivatives, paclitaxel and its functional and structural derivatives. Examples of rapamycin derivatives include ABT-578, 40-O-(3-hydroxy)propyl-rapamycin, 40-O-[2-(2-hydroxy)ethoxy]ethyl-rapamycin, and 40-O-tetrazole-rapamycin. Examples of paclitaxel derivatives include docetaxel. Examples of antineoplastics and/or antimitotics include methotrexate, azathioprine, vincristine, vinblastine, fluorouracil, doxorubicin hydrochloride (e.g. Adriamycin® from Pharmacia & Upjohn, Peapack N.J.), and mitomycin (e.g. Mutamycin® from Bristol-Myers Squibb Co., Stamford, Conn.). Examples of such antiplatelets, anticoagulants, antifibrin, and antithrombins include sodium heparin, low molecular weight heparins, heparinoids, hirudin, argatroban, forskolin, vapiprost, prostacyclin and prostacyclin analogues, dextran, D-phe-pro-arg-chloromethylketone (synthetic antithrombin), dipyridamole, glycoprotein IIb/IIIa platelet membrane receptor antagonist antibody, recombinant hirudin, thrombin inhibitors such as Angiomax (Biogen, Inc., Cambridge, Mass.), calcium channel blockers (such as nifedipine), colchicine, fibroblast growth factor (FGF) antagonists, fish oil (omega 3-fatty acid), histamine antagonists, lovastatin (an inhibitor of HMG-CoA reductase, a cholesterol lowering drug, brand name Mevacor® from Merck & Co., Inc., Whitehouse Station, N.J.), monoclonal antibodies (such as those specific for Platelet-Derived Growth Factor (PDGF) receptors), nitroprusside, phosphodiesterase inhibitors, prostaglandin inhibitors, suramin, serotonin blockers, steroids, thioprotease inhibitors, triazolopyrimidine (a PDGF antagonist), super oxide dismutases, super oxide dismutase mimetic, 4-amino-2,2,6,6-tetramethylpiperidine-1-oxyl (4-amino-TEMPO), estradiol, anticancer agents, dietary supplements such as various vitamins, and a combination thereof. Examples of anti-inflammatory agents including steroidal and non-steroidal anti-inflammatory agents include biolimus, tacrolimus, dexamethasone, clobetasol, corticosteroids or combinations thereof. Examples of such cytostatic substance include angiopeptin, angiotensin converting enzyme inhibitors such as captopril (e.g. Capoten® and Capozide® from Bristol-Myers Squibb Co., Stamford, Conn.), cilazapril or lisinopril (e.g. Prinivil® and Prinzide® from Merck & Co., Inc., Whitehouse Station, N.J.). An example of an antiallergic agent is permirolast potassium. Other therapeutic substances or agents which may be appropriate include alpha-interferon, pimecrolimus, imatinib mesylate, midostaurin, and genetically engineered epithelial cells. The foregoing substances can also be used in the form of prodrugs or co-drugs thereof. The foregoing substances also include metabolites thereof and/or prodrugs of the metabolites. The foregoing substances are listed by way of example and are not meant to be limiting. Other active agents which are currently available or that may be developed in the future are equally applicable.
The dosage or concentration of the bioactive agent required to produce a favorable therapeutic effect should be less than the level at which the bioactive agent produces toxic effects and greater than the level at which non-therapeutic results are obtained. The dosage or concentration of the bioactive agent can depend upon factors such as the particular circumstances of the patient, the nature of the trauma, the nature of the therapy desired, the time over which the ingredient administered resides at the vascular site, and if other active agents are employed, the nature and type of the substance or combination of substances. Therapeutically effective dosages can be determined empirically, for example by infusing vessels from suitable animal model systems and using immunohistochemical, fluorescent or electron microscopy methods to detect the agent and its effects, or by conducting suitable in vitro studies. Standard pharmacological test procedures to determine dosages are understood by those of ordinary skill in the art.
As used herein, an implantable device can be any suitable medical substrate that can be implanted in a human or veterinary patient. Examples of such implantable devices include self-expandable stents, balloon-expandable stents, stent-grafts, grafts (e.g., aortic grafts), heart valve prosthesis (e.g., artificial heart valves) or vascular graft, cerebrospinal fluid shunts, pacemaker electrodes, catheters, endocardial leads (e.g.; FINELINE and ENDOTAK, available from Guidant Corporation, Santa Clara, Calif.), and devices facilitating anastomosis such as anastomotic connectors. The underlying structure of the device can be of virtually any design. The device can include a metallic material or an alloy such as, but not limited to, cobalt chromium alloy (ELGILOY), stainless steel (316L), high nitrogen stainless steel, e.g., BIODUR 108, cobalt chrome alloy L-605, “MP35N,” “MP20N,” ELASTINITE (Nitinol), tantalum, nickel-titanium alloy, platinum-iridium alloy, gold, magnesium, or combinations thereof. “MP35N” and “MP20N” are trade names for alloys of cobalt, nickel, chromium and molybdenum available from Standard Press Steel Co., Jenkintown, Pa. “MP35N” consists of 35% cobalt, 35% nickel, 20% chromium, and 10% molybdenum. “MP20N” consists of 50% cobalt, 20% nickel, 20% chromium, and 10% molybdenum. Devices made from bioabsorbable or biostable polymers could also be used with the embodiments of the present invention. The device can be, for example, a bioabsorbable stent.
In accordance with embodiments of the invention, a chemo-attractant can be attached to a medical device or prosthesis, e.g., a stent. For a device including one or more active agents, the agent will retain on the device such as a stent during delivery and expansion of the device, and released at a desired rate and for a predetermined duration of time at the site of implantation.
Preferably, the device is a stent. The stent described herein is useful for a variety of medical procedures, including, by way of example, treatment of obstructions caused by tumors in the bile ducts, esophagus, trachea/bronchi and other biological passageways. A stent having the above-described coating is particularly useful for treating occluded regions of blood vessels caused by abnormal or inappropriate migration and proliferation of smooth muscle cells, thrombosis, and restenosis. Stents may be placed in a wide array of blood vessels, both arteries and veins. Representative examples of sites include the iliac, renal, and coronary arteries.
For implantation of a stent, an angiogram is first performed to determine the appropriate positioning for stent therapy. An angiogram is typically accomplished by injecting a radiopaque contrasting agent through a catheter inserted into an artery or vein as an x-ray is taken. A guidewire is then advanced through the lesion or proposed site of treatment. Over the guidewire is passed a delivery catheter that allows a stent in its collapsed configuration to be inserted into the passageway. The delivery catheter is inserted either percutaneously or by surgery into the femoral artery, brachial artery, femoral vein, or brachial vein, and advanced into the appropriate blood vessel by steering the catheter through the vascular system under fluoroscopic guidance. A stent having the above-described coating may then be expanded at the desired area of treatment. A post-insertion angiogram may also be utilized to confirm appropriate positioning.
While particular embodiments of the present invention have been shown and described, it will be obvious to those skilled in the art that changes and modifications can be made without departing from this invention in its broader aspects. Therefore, the appended claims are to encompass within their scope all such changes and modifications as fall within the true spirit and scope of this invention.
Number | Name | Date | Kind |
---|---|---|---|
2072303 | Herrmann et al. | Mar 1937 | A |
2386454 | Frosch et al. | Oct 1945 | A |
3773737 | Goodman et al. | Nov 1973 | A |
3849514 | Gray, Jr. et al. | Nov 1974 | A |
4226243 | Shalaby et al. | Oct 1980 | A |
4329383 | Joh | May 1982 | A |
4343931 | Barrows | Aug 1982 | A |
4529792 | Barrows | Jul 1985 | A |
4611051 | Hayes et al. | Sep 1986 | A |
4656242 | Swan et al. | Apr 1987 | A |
4733665 | Palmaz | Mar 1988 | A |
4800882 | Gianturco | Jan 1989 | A |
4882168 | Casey et al. | Nov 1989 | A |
4886062 | Wiktor | Dec 1989 | A |
4931287 | Bae et al. | Jun 1990 | A |
4941870 | Okada et al. | Jul 1990 | A |
4977901 | Ofstead | Dec 1990 | A |
5019096 | Fox, Jr. et al. | May 1991 | A |
5100992 | Cohn et al. | Mar 1992 | A |
5112457 | Marchant | May 1992 | A |
5133742 | Pinchuk | Jul 1992 | A |
5163952 | Froix | Nov 1992 | A |
5165919 | Sasaki et al. | Nov 1992 | A |
5213580 | Slepian et al. | May 1993 | A |
5219980 | Swidler | Jun 1993 | A |
5258020 | Froix | Nov 1993 | A |
5272012 | Opolski | Dec 1993 | A |
5292516 | Viegas et al. | Mar 1994 | A |
5298260 | Viegas et al. | Mar 1994 | A |
5300295 | Viegas et al. | Apr 1994 | A |
5306501 | Viegas et al. | Apr 1994 | A |
5306786 | Moens et al. | Apr 1994 | A |
5328471 | Slepian | Jul 1994 | A |
5330768 | Park et al. | Jul 1994 | A |
5380299 | Fearnot et al. | Jan 1995 | A |
5383928 | Scott et al. | Jan 1995 | A |
5417981 | Endo et al. | May 1995 | A |
5447724 | Helmus et al. | Sep 1995 | A |
5455040 | Marchant | Oct 1995 | A |
5462990 | Hubbell et al. | Oct 1995 | A |
5464650 | Berg et al. | Nov 1995 | A |
5485496 | Lee et al. | Jan 1996 | A |
5516881 | Lee et al. | May 1996 | A |
5569463 | Helmus et al. | Oct 1996 | A |
5575815 | Slepian et al. | Nov 1996 | A |
5578073 | Haimovich et al. | Nov 1996 | A |
5584877 | Miyake et al. | Dec 1996 | A |
5605696 | Eury et al. | Feb 1997 | A |
5607467 | Froix | Mar 1997 | A |
5607475 | Cahalan et al. | Mar 1997 | A |
5609629 | Fearnot et al. | Mar 1997 | A |
5610241 | Lee et al. | Mar 1997 | A |
5616338 | Fox, Jr. et al. | Apr 1997 | A |
5624411 | Tuch | Apr 1997 | A |
5628730 | Shapland et al. | May 1997 | A |
5644020 | Timmermann et al. | Jul 1997 | A |
5649977 | Campbell | Jul 1997 | A |
5658995 | Kohn et al. | Aug 1997 | A |
5667767 | Greff et al. | Sep 1997 | A |
5670558 | Onishi et al. | Sep 1997 | A |
5674242 | Phan et al. | Oct 1997 | A |
5679400 | Tuch | Oct 1997 | A |
5700286 | Tartaglia et al. | Dec 1997 | A |
5702754 | Zhong | Dec 1997 | A |
5711958 | Cohn et al. | Jan 1998 | A |
5716981 | Hunter et al. | Feb 1998 | A |
5721131 | Rudolph et al. | Feb 1998 | A |
5723219 | Kolluri et al. | Mar 1998 | A |
5725568 | Hastings | Mar 1998 | A |
5735897 | Buirge | Apr 1998 | A |
5746998 | Torchilin et al. | May 1998 | A |
5759205 | Valentini | Jun 1998 | A |
5776184 | Tuch | Jul 1998 | A |
5782908 | Cahalan et al. | Jul 1998 | A |
5783657 | Pavlin et al. | Jul 1998 | A |
5788979 | Alt et al. | Aug 1998 | A |
5800392 | Racchini | Sep 1998 | A |
5820917 | Tuch | Oct 1998 | A |
5824048 | Tuch | Oct 1998 | A |
5824049 | Ragheb et al. | Oct 1998 | A |
5830178 | Jones et al. | Nov 1998 | A |
5837008 | Berg et al. | Nov 1998 | A |
5837313 | Ding et al. | Nov 1998 | A |
5843156 | Slepian et al. | Dec 1998 | A |
5849859 | Acemoglu | Dec 1998 | A |
5851508 | Greff et al. | Dec 1998 | A |
5854376 | Higashi | Dec 1998 | A |
5857998 | Barry | Jan 1999 | A |
5858746 | Hubbell et al. | Jan 1999 | A |
5865814 | Tuch | Feb 1999 | A |
5869127 | Zhong | Feb 1999 | A |
5873904 | Ragheb et al. | Feb 1999 | A |
5874165 | Drumheller | Feb 1999 | A |
5876433 | Lunn | Mar 1999 | A |
5877224 | Brocchini et al. | Mar 1999 | A |
5879713 | Roth et al. | Mar 1999 | A |
5891192 | Murayama et al. | Apr 1999 | A |
5897955 | Drumheller | Apr 1999 | A |
5902875 | Roby et al. | May 1999 | A |
5905168 | Dos Santos et al. | May 1999 | A |
5910564 | Gruning et al. | Jun 1999 | A |
5914182 | Drumheller | Jun 1999 | A |
5914387 | Roby et al. | Jun 1999 | A |
5919893 | Roby et al. | Jul 1999 | A |
5925720 | Kataoka et al. | Jul 1999 | A |
5932299 | Katoot | Aug 1999 | A |
5955509 | Webber et al. | Sep 1999 | A |
5958385 | Tondeur et al. | Sep 1999 | A |
5962138 | Kolluri et al. | Oct 1999 | A |
5971954 | Conway et al. | Oct 1999 | A |
5980928 | Terry | Nov 1999 | A |
5980972 | Ding | Nov 1999 | A |
5997517 | Whitbourne | Dec 1999 | A |
6010530 | Goicoechea | Jan 2000 | A |
6011125 | Lohmeijer et al. | Jan 2000 | A |
6015541 | Greff et al. | Jan 2000 | A |
6033582 | Lee et al. | Mar 2000 | A |
6034204 | Mohr et al. | Mar 2000 | A |
6042875 | Ding et al. | Mar 2000 | A |
6051576 | Ashton et al. | Apr 2000 | A |
6051648 | Rhee et al. | Apr 2000 | A |
6054553 | Groth et al. | Apr 2000 | A |
6056993 | Leidner et al. | May 2000 | A |
6060451 | DiMaio et al. | May 2000 | A |
6060518 | Kabanov et al. | May 2000 | A |
6080488 | Hostettler et al. | Jun 2000 | A |
6087479 | Stamler et al. | Jul 2000 | A |
6096070 | Ragheb et al. | Aug 2000 | A |
6099562 | Ding et al. | Aug 2000 | A |
6110188 | Narciso, Jr. | Aug 2000 | A |
6110483 | Whitbourne et al. | Aug 2000 | A |
6113629 | Ken | Sep 2000 | A |
6120491 | Kohn et al. | Sep 2000 | A |
6120536 | Ding et al. | Sep 2000 | A |
6120788 | Barrows | Sep 2000 | A |
6120904 | Hostettler et al. | Sep 2000 | A |
6121027 | Clapper et al. | Sep 2000 | A |
6129761 | Hubbell | Oct 2000 | A |
6136333 | Cohn et al. | Oct 2000 | A |
6143354 | Koulik et al. | Nov 2000 | A |
6153252 | Hossainy et al. | Nov 2000 | A |
6159978 | Myers et al. | Dec 2000 | A |
6165212 | Dereume et al. | Dec 2000 | A |
6172167 | Stapert et al. | Jan 2001 | B1 |
6174539 | Stamler et al. | Jan 2001 | B1 |
6177523 | Reich et al. | Jan 2001 | B1 |
6180632 | Myers et al. | Jan 2001 | B1 |
6203551 | Wu | Mar 2001 | B1 |
6211249 | Cohn et al. | Apr 2001 | B1 |
6214901 | Chudzik et al. | Apr 2001 | B1 |
6231600 | Zhong | May 2001 | B1 |
6240616 | Yan | Jun 2001 | B1 |
6245753 | Byun et al. | Jun 2001 | B1 |
6245760 | He et al. | Jun 2001 | B1 |
6248129 | Froix | Jun 2001 | B1 |
6251136 | Guruwaiya et al. | Jun 2001 | B1 |
6254632 | Wu et al. | Jul 2001 | B1 |
6258121 | Yang et al. | Jul 2001 | B1 |
6258371 | Koulik et al. | Jul 2001 | B1 |
6262034 | Mathiowitz et al. | Jul 2001 | B1 |
6270788 | Koulik et al. | Aug 2001 | B1 |
6277449 | Kolluri et al. | Aug 2001 | B1 |
6283947 | Mirzaee | Sep 2001 | B1 |
6283949 | Roorda | Sep 2001 | B1 |
6284305 | Ding et al. | Sep 2001 | B1 |
6287628 | Hossainy et al. | Sep 2001 | B1 |
6299604 | Ragheb et al. | Oct 2001 | B1 |
6306176 | Whitbourne | Oct 2001 | B1 |
6331313 | Wong et al. | Dec 2001 | B1 |
6335029 | Kamath et al. | Jan 2002 | B1 |
6344035 | Chudzik et al. | Feb 2002 | B1 |
6346110 | Wu | Feb 2002 | B2 |
6358556 | Ding et al. | Mar 2002 | B1 |
6379379 | Wang | Apr 2002 | B1 |
6379381 | Hossainy et al. | Apr 2002 | B1 |
6379382 | Yang | Apr 2002 | B1 |
6387379 | Goldberg et al. | May 2002 | B1 |
6395326 | Castro et al. | May 2002 | B1 |
6419692 | Yang et al. | Jul 2002 | B1 |
6451373 | Hossainy et al. | Sep 2002 | B1 |
6471978 | Stamler et al. | Oct 2002 | B1 |
6475779 | Mathiowitz et al. | Nov 2002 | B2 |
6482834 | Spada et al. | Nov 2002 | B2 |
6494862 | Ray et al. | Dec 2002 | B1 |
6497729 | Moussy et al. | Dec 2002 | B1 |
6503538 | Chu et al. | Jan 2003 | B1 |
6503556 | Harish et al. | Jan 2003 | B2 |
6503954 | Bhat et al. | Jan 2003 | B1 |
6506408 | Palasis | Jan 2003 | B1 |
6506437 | Harish et al. | Jan 2003 | B1 |
6514734 | Clapper et al. | Feb 2003 | B1 |
6524347 | Myers et al. | Feb 2003 | B1 |
6527801 | Dutta | Mar 2003 | B1 |
6527863 | Pacetti et al. | Mar 2003 | B1 |
6528526 | Myers et al. | Mar 2003 | B1 |
6530950 | Alvarado et al. | Mar 2003 | B1 |
6530951 | Bates et al. | Mar 2003 | B1 |
6540776 | Sanders Millare et al. | Apr 2003 | B2 |
6544223 | Kokish | Apr 2003 | B1 |
6544543 | Mandrusov et al. | Apr 2003 | B1 |
6544582 | Yoe | Apr 2003 | B1 |
6555157 | Hossainy | Apr 2003 | B1 |
6558733 | Hossainy et al. | May 2003 | B1 |
6565659 | Pacetti et al. | May 2003 | B1 |
6572644 | Moein | Jun 2003 | B1 |
6585755 | Jackson et al. | Jul 2003 | B2 |
6585765 | Hossainy et al. | Jul 2003 | B1 |
6585926 | Mirzaee | Jul 2003 | B1 |
6605154 | Villareal | Aug 2003 | B1 |
6613082 | Yang | Sep 2003 | B2 |
6613084 | Yang | Sep 2003 | B2 |
6613432 | Zamora et al. | Sep 2003 | B2 |
6616765 | Hossaony et al. | Sep 2003 | B1 |
6620617 | Mathiowitz et al. | Sep 2003 | B2 |
6623448 | Slater | Sep 2003 | B2 |
6623521 | Steinke et al. | Sep 2003 | B2 |
6625486 | Lundkvist et al. | Sep 2003 | B2 |
6641611 | Jayaraman | Nov 2003 | B2 |
6645135 | Bhat | Nov 2003 | B1 |
6645195 | Bhat et al. | Nov 2003 | B1 |
6652575 | Wang | Nov 2003 | B2 |
6656216 | Hossainy et al. | Dec 2003 | B1 |
6656506 | Wu et al. | Dec 2003 | B1 |
6660034 | Mandrusov et al. | Dec 2003 | B1 |
6663662 | Pacetti et al. | Dec 2003 | B2 |
6663880 | Roorda et al. | Dec 2003 | B1 |
6666880 | Chiu et al. | Dec 2003 | B1 |
6673154 | Pacetti et al. | Jan 2004 | B1 |
6673385 | Ding et al. | Jan 2004 | B1 |
6689099 | Mirzaee | Feb 2004 | B2 |
6689350 | Uhrich | Feb 2004 | B2 |
6695920 | Pacetti et al. | Feb 2004 | B1 |
6706013 | Bhat et al. | Mar 2004 | B1 |
6709514 | Hossainy | Mar 2004 | B1 |
6712845 | Hossainy | Mar 2004 | B2 |
6713119 | Hossainy et al. | Mar 2004 | B2 |
6716444 | Castro et al. | Apr 2004 | B1 |
6723120 | Yan | Apr 2004 | B2 |
6730064 | Ragheb et al. | May 2004 | B2 |
6733768 | Hossainy et al. | May 2004 | B2 |
6740040 | Mandrusov et al. | May 2004 | B1 |
6743462 | Pacetti | Jun 2004 | B1 |
6746773 | Llanos et al. | Jun 2004 | B2 |
6749626 | Bhat et al. | Jun 2004 | B1 |
6753071 | Pacetti et al. | Jun 2004 | B1 |
6758859 | Dang et al. | Jul 2004 | B1 |
6759054 | Chen et al. | Jul 2004 | B2 |
6764505 | Hossainy et al. | Jul 2004 | B1 |
6776796 | Falotico et al. | Aug 2004 | B2 |
6780424 | Claude | Aug 2004 | B2 |
6790228 | Hossainy et al. | Sep 2004 | B2 |
6824559 | Michal | Nov 2004 | B2 |
6861088 | Weber et al. | Mar 2005 | B2 |
6865810 | Stinson | Mar 2005 | B2 |
6869443 | Buscemi et al. | Mar 2005 | B2 |
6878160 | Gilligan et al. | Apr 2005 | B2 |
6887270 | Miller et al. | May 2005 | B2 |
6887485 | Fitzhugh et al. | May 2005 | B2 |
6890546 | Mollison et al. | May 2005 | B2 |
6890583 | Chudzik et al. | May 2005 | B2 |
6899731 | Li et al. | May 2005 | B2 |
7008667 | Chudzik et al. | Mar 2006 | B2 |
7229471 | Gale et al. | Jun 2007 | B2 |
20010007083 | Roorda | Jul 2001 | A1 |
20010029351 | Falotico et al. | Oct 2001 | A1 |
20010037145 | Guruwaiya et al. | Nov 2001 | A1 |
20020005206 | Falotico et al. | Jan 2002 | A1 |
20020007213 | Falotico et al. | Jan 2002 | A1 |
20020007214 | Falotico | Jan 2002 | A1 |
20020007215 | Falotico et al. | Jan 2002 | A1 |
20020051730 | Bodnar et al. | May 2002 | A1 |
20020077693 | Barclay et al. | Jun 2002 | A1 |
20020082679 | Sirhan et al. | Jun 2002 | A1 |
20020087123 | Hossainy et al. | Jul 2002 | A1 |
20020091433 | Ding et al. | Jul 2002 | A1 |
20020111590 | Davila et al. | Aug 2002 | A1 |
20020165601 | Clerc | Nov 2002 | A1 |
20020165608 | Llanos et al. | Nov 2002 | A1 |
20020176849 | Slepian | Nov 2002 | A1 |
20020183581 | Yoe et al. | Dec 2002 | A1 |
20020188037 | Chudzik et al. | Dec 2002 | A1 |
20020188277 | Roorda et al. | Dec 2002 | A1 |
20030004141 | Brown | Jan 2003 | A1 |
20030028243 | Bates et al. | Feb 2003 | A1 |
20030028244 | Bates et al. | Feb 2003 | A1 |
20030032767 | Tada et al. | Feb 2003 | A1 |
20030036794 | Ragheb et al. | Feb 2003 | A1 |
20030039689 | Chen et al. | Feb 2003 | A1 |
20030040790 | Furst | Feb 2003 | A1 |
20030059520 | Chen et al. | Mar 2003 | A1 |
20030060877 | Falotico et al. | Mar 2003 | A1 |
20030065377 | Davila et al. | Apr 2003 | A1 |
20030072868 | Harish et al. | Apr 2003 | A1 |
20030073961 | Happ | Apr 2003 | A1 |
20030083646 | Sirhan et al. | May 2003 | A1 |
20030083739 | Cafferata | May 2003 | A1 |
20030097088 | Pacetti | May 2003 | A1 |
20030097173 | Dutta | May 2003 | A1 |
20030099712 | Jayaraman | May 2003 | A1 |
20030105518 | Dutta | Jun 2003 | A1 |
20030113439 | Pacetti et al. | Jun 2003 | A1 |
20030150380 | Yoe | Aug 2003 | A1 |
20030157241 | Hossainy et al. | Aug 2003 | A1 |
20030158517 | Kokish | Aug 2003 | A1 |
20030190406 | Hossainy et al. | Oct 2003 | A1 |
20030207020 | Villareal | Nov 2003 | A1 |
20030211230 | Pacetti et al. | Nov 2003 | A1 |
20040018296 | Castro et al. | Jan 2004 | A1 |
20040029952 | Chen et al. | Feb 2004 | A1 |
20040047978 | Hossainy et al. | Mar 2004 | A1 |
20040047980 | Pacetti et al. | Mar 2004 | A1 |
20040052858 | Wu et al. | Mar 2004 | A1 |
20040052859 | Wu et al. | Mar 2004 | A1 |
20040054104 | Pacetti | Mar 2004 | A1 |
20040060508 | Pacetti et al. | Apr 2004 | A1 |
20040062853 | Pacetti et al. | Apr 2004 | A1 |
20040063805 | Pacetti et al. | Apr 2004 | A1 |
20040071861 | Mandrusov et al. | Apr 2004 | A1 |
20040072922 | Hossainy et al. | Apr 2004 | A1 |
20040073298 | Hossainy | Apr 2004 | A1 |
20040086542 | Hossainy et al. | May 2004 | A1 |
20040086550 | Roorda et al. | May 2004 | A1 |
20040096504 | Michal | May 2004 | A1 |
20040098117 | Hossainy et al. | May 2004 | A1 |
20040106985 | Jang | Jun 2004 | A1 |
20040172121 | Eidenschink et al. | Sep 2004 | A1 |
20040172127 | Kantor | Sep 2004 | A1 |
20040236415 | Thomas | Nov 2004 | A1 |
20050037052 | Udipi et al. | Feb 2005 | A1 |
20050038134 | Loomis et al. | Feb 2005 | A1 |
20050038497 | Neuendorf et al. | Feb 2005 | A1 |
20050043786 | Chu et al. | Feb 2005 | A1 |
20050049693 | Walker | Mar 2005 | A1 |
20050049694 | Neary | Mar 2005 | A1 |
20050054774 | Kangas | Mar 2005 | A1 |
20050055044 | Kangas | Mar 2005 | A1 |
20050055078 | Campbell | Mar 2005 | A1 |
20050060020 | Jenson | Mar 2005 | A1 |
20050064088 | Fredrickson | Mar 2005 | A1 |
20050065501 | Wallace | Mar 2005 | A1 |
20050065545 | Wallace | Mar 2005 | A1 |
20050065593 | Chu et al. | Mar 2005 | A1 |
20050074406 | Couvillon, Jr. et al. | Apr 2005 | A1 |
20050074545 | Thomas | Apr 2005 | A1 |
20050075714 | Cheng et al. | Apr 2005 | A1 |
20050079274 | Palasis et al. | Apr 2005 | A1 |
20050084515 | Udipi et al. | Apr 2005 | A1 |
20050095267 | Campbell et al. | May 2005 | A1 |
20050106210 | Ding et al. | May 2005 | A1 |
20050113903 | Rosenthal et al. | May 2005 | A1 |
20060058868 | Gale et al. | Mar 2006 | A1 |
20060115514 | Gengrinovitch | Jun 2006 | A1 |
Number | Date | Country |
---|---|---|
42 24 401 | Jan 1994 | DE |
0 301 856 | Feb 1989 | EP |
0 396 429 | Nov 1990 | EP |
0 514 406 | Nov 1992 | EP |
0 604 022 | Jun 1994 | EP |
0 623 354 | Nov 1994 | EP |
0 665 023 | Aug 1995 | EP |
0 701 802 | Mar 1996 | EP |
0 716 836 | Jun 1996 | EP |
0 809 999 | Dec 1997 | EP |
0 832 655 | Apr 1998 | EP |
0 850 651 | Jul 1998 | EP |
0 879 595 | Nov 1998 | EP |
0 910 584 | Apr 1999 | EP |
0 923 953 | Jun 1999 | EP |
0 953 320 | Nov 1999 | EP |
0 970 711 | Jan 2000 | EP |
0 982 041 | Mar 2000 | EP |
1 023 879 | Aug 2000 | EP |
1 192 957 | Apr 2002 | EP |
1 273 314 | Jan 2003 | EP |
2001-190687 | Jul 2001 | JP |
872531 | Oct 1981 | SU |
876663 | Oct 1981 | SU |
905228 | Feb 1982 | SU |
790725 | Feb 1983 | SU |
1016314 | May 1983 | SU |
811750 | Sep 1983 | SU |
1293518 | Feb 1987 | SU |
WO 9112846 | Sep 1991 | WO |
WO 9409760 | May 1994 | WO |
WO 9510989 | Apr 1995 | WO |
WO 9524929 | Sep 1995 | WO |
WO 9640174 | Dec 1996 | WO |
WO 9710011 | Mar 1997 | WO |
WO 9745105 | Dec 1997 | WO |
WO 9746590 | Dec 1997 | WO |
WO 9808463 | Mar 1998 | WO |
WO 9817331 | Apr 1998 | WO |
WO 9832398 | Jul 1998 | WO |
WO 9836784 | Aug 1998 | WO |
WO 9901118 | Jan 1999 | WO |
WO 9938546 | Aug 1999 | WO |
WO 9963981 | Dec 1999 | WO |
WO 0002599 | Jan 2000 | WO |
WO 0012147 | Mar 2000 | WO |
WO 0018446 | Apr 2000 | WO |
WO 0062630 | Oct 2000 | WO |
WO 0064506 | Nov 2000 | WO |
WO 0101890 | Jan 2001 | WO |
WO 0115751 | Mar 2001 | WO |
WO 0117577 | Mar 2001 | WO |
WO 0145763 | Jun 2001 | WO |
WO 0149338 | Jul 2001 | WO |
WO 0151027 | Jul 2001 | WO |
WO 0174414 | Oct 2001 | WO |
WO 0203890 | Jan 2002 | WO |
WO 0226162 | Apr 2002 | WO |
WO 0234311 | May 2002 | WO |
WO 02056790 | Jul 2002 | WO |
WO 02058753 | Aug 2002 | WO |
WO 02102283 | Dec 2002 | WO |
WO 03000308 | Jan 2003 | WO |
WO 03022323 | Mar 2003 | WO |
WO 03028780 | Apr 2003 | WO |
WO 03037223 | May 2003 | WO |
WO 03039612 | May 2003 | WO |
WO 03080147 | Oct 2003 | WO |
WO 03082368 | Oct 2003 | WO |
WO 03080147 | Oct 2003 | WO |
WO 04000383 | Dec 2003 | WO |
WO 2004009145 | Jan 2004 | WO |
WO 2005117832 | Dec 2005 | WO |
WO 2005117832 | Dec 2005 | WO |
WO 2006056984 | Jun 2006 | WO |
WO 2006112932 | Oct 2006 | WO |
WO 2006112932 | Oct 2006 | WO |
WO 2007097887 | Aug 2007 | WO |
Number | Date | Country | |
---|---|---|---|
20070293941 A1 | Dec 2007 | US |